How should medical oncologists and dermatologists communicate about patients with at least Stage IIB/III cutaneous melanoma regarding neoadjuvant immunotherapy?
Some medical oncologists may get referrals for patients after a shave biopsy leads to WLE, thus removing the primary and its opportunity for antigens to be present, and may not be aware of the T stage, given a shave biopsy on diagnosis. What have you or your institution done in practice to facilitate these referrals?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Ohio State University Comprehensive Cancer Center
Answered on
Only melanoma patients with stage III or resectable stage IV disease should be treated with standard-of-care neoadjuvant immunotherapy.
These patients should see a medical oncologist first (and no longer last, as is the current process). I would recommend that the schedulers at your institution be e...
Join for free or sign in to see the full answer